Timelines of events, such as symptom appearance or a change in biomarker value, provide powerful signatures that characterise progressive diseases. Understanding and predicting the timing of events is important for clinical trials targeting individuals early in the disease course when putative treatments are likely to have the strongest effect. However, previous models of disease progression cannot estimate the time between events and provide only an ordering in which they change. Here, we introduce the temporal event-based model (TEBM), a new probabilistic model for inferring timelines of biomarker events from sparse and irregularly sampled datasets. We demonstrate the power of the TEBM in two neurodegenerative conditions: Alzheimer's dise...
The event-based model (EBM) for data-driven disease progression modeling estimates the sequence in w...
International audienceAlzheimer's disease (AD) is characterized by complex and largely unknown progr...
Objective: Determining the sequence in which Huntington's disease biomarkers become abnormal can pro...
Timelines of events, such as symptom appearance or a change in biomarker value, provide powerful sig...
Timelines of events, such as symptom appearance or a change in biomarker value, provide powerful sig...
Alzheimer's Disease (AD) is characterized by a cascade of biomarkers becoming abnormal, the pathophy...
Progressive diseases worsen over time and are characterised by monotonic change in features that t...
Understanding the progression of neurological diseases is vital for accurate and early diagnosis and...
textabstractThe event-based model (EBM) for data-driven disease progression modeling estimates the s...
Abstract Background Alzheimer’s disease and related dementia (ADRD) are characterized by multiple an...
Understanding the progression of neurological diseases is vital for accurate and early diagnosis and...
Data-driven disease progression models have provided important insight into the timeline of brain ch...
Data-driven disease progression models have provided important insight into the timeline of brain ch...
Introduction: Characterization of longitudinal trajectories of biomarkers implicated in sporadic Alz...
The event-based model (EBM) for data-driven disease progression modeling estimates the sequence in w...
The event-based model (EBM) for data-driven disease progression modeling estimates the sequence in w...
International audienceAlzheimer's disease (AD) is characterized by complex and largely unknown progr...
Objective: Determining the sequence in which Huntington's disease biomarkers become abnormal can pro...
Timelines of events, such as symptom appearance or a change in biomarker value, provide powerful sig...
Timelines of events, such as symptom appearance or a change in biomarker value, provide powerful sig...
Alzheimer's Disease (AD) is characterized by a cascade of biomarkers becoming abnormal, the pathophy...
Progressive diseases worsen over time and are characterised by monotonic change in features that t...
Understanding the progression of neurological diseases is vital for accurate and early diagnosis and...
textabstractThe event-based model (EBM) for data-driven disease progression modeling estimates the s...
Abstract Background Alzheimer’s disease and related dementia (ADRD) are characterized by multiple an...
Understanding the progression of neurological diseases is vital for accurate and early diagnosis and...
Data-driven disease progression models have provided important insight into the timeline of brain ch...
Data-driven disease progression models have provided important insight into the timeline of brain ch...
Introduction: Characterization of longitudinal trajectories of biomarkers implicated in sporadic Alz...
The event-based model (EBM) for data-driven disease progression modeling estimates the sequence in w...
The event-based model (EBM) for data-driven disease progression modeling estimates the sequence in w...
International audienceAlzheimer's disease (AD) is characterized by complex and largely unknown progr...
Objective: Determining the sequence in which Huntington's disease biomarkers become abnormal can pro...